A pharmacokinetic analysis of molecular cardiac surgery with recirculation mediated delivery of βARKct gene therapy: developing a quantitative definition of the therapeutic window.

[1]  M. Katz,et al.  Current strategies for myocardial gene delivery. , 2011, Journal of molecular and cellular cardiology.

[2]  D. Leosco,et al.  GRK2 as a novel gene therapy target in heart failure. , 2011, Journal of molecular and cellular cardiology.

[3]  W. Koch,et al.  Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo , 2011, Gene Therapy.

[4]  M. Katz,et al.  Gene therapy during cardiac surgery: role of surgical technique to minimize collateral organ gene expression. , 2010, Interactive cardiovascular and thoracic surgery.

[5]  W. Koch,et al.  Comparative Cardiac Gene Delivery of Adeno‐Associated Virus Serotypes 1–9 reveals that AAV6 Mediates the Most Efficient Transduction in Mouse Heart , 2010, Clinical and translational science.

[6]  C. Bridges.  ‘Recirculating cardiac delivery’ method of gene delivery should be called ‘non-recirculating’ method , 2009, Gene Therapy.

[7]  D. Mancini,et al.  Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. , 2009, Journal of cardiac failure.

[8]  W. Koch,et al.  Myocardial Adeno-Associated Virus Serotype 6–&bgr;ARKct Gene Therapy Improves Cardiac Function and Normalizes the Neurohormonal Axis in Chronic Heart Failure , 2009, Circulation.

[9]  W. Koch,et al.  Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy. , 2007, Journal of cardiac failure.

[10]  R. Samulski,et al.  Adeno-associated virus serotypes: vector toolkit for human gene therapy. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  H. Sundar,et al.  Efficient myocyte gene delivery with complete cardiac surgical isolation in situ. , 2005, The Journal of thoracic and cardiovascular surgery.

[12]  W. Koch,et al.  Dose dependent effects of cardiac β2 adrenoceptor gene therapy1 , 2004 .

[13]  Robert J Lederman,et al.  Incomplete retention after direct myocardial injection , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[14]  J. Michel,et al.  How to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures? , 2001, Human gene therapy.

[15]  James M. Allen,et al.  Adeno-Associated Virus Type 6 (AAV6) Vectors Mediate Efficient Transduction of Airway Epithelial Cells in Mouse Lungs Compared to That of AAV2 Vectors , 2001, Journal of Virology.

[16]  P. Boekstegers,et al.  Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins , 2000, Gene Therapy.

[17]  P. Boekstegers,et al.  Selective pressure-regulated retroinfusion of coronary veins as an alternative access of ischemic myocardium: implications for myocardial protection, myocardial gene transfer and angiogenesis , 2000, Zeitschrift für Kardiologie.

[18]  R. Balice-Gordon,et al.  Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector , 1999, Nature Medicine.

[19]  E. Marbán,et al.  Ultrarapid, highly efficient viral gene transfer to the heart. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Strumpf,et al.  Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. , 1996, The Annals of thoracic surgery.